Oxidative deamination of alicyclic primary amines by liver microsomes from rats and rabbits

Ring Nitrogenation of Aromatic Amines by the Excited State of an Osmium(VI) Nitrido Complex

The reactivity of electrophilic Os^VI and Ru^VI nitrides toward various aliphatic and aromatic amines have been previously reported; these reactions all go through an initial nucleophilic addition of the amine nitrogen to M^VI≡N (M = Os, Ru) to generate a M^IV hydrazido species. Herein, we report that the excited state of a luminescent osmium(VI) nitrido complex, [Os^VI(N)(L)(CN)₃]^- (OsN, HL = 2-(2-hydroxy-5-nitrophenyl)benzoxazole), undergoes unprecedented ring nitrogenation of aromatic amines. Visible-light irradiation of OsN generates OsN*, which predominantly attacks the aromatic ring of 2,6-dimethylaniline (Me₂PhNH₂) to give an Os(II) benzoquinone diimine compound (PPh₄)[Os^II(L)(CN)₃(p-NH═Me₂Ph═NH₂)] [(PPh₄)2] in 60% yield, while nucleophilic addition of the amine N to OsN* also occurs to give the osmium(II) diazonium compound (PPh₄)[Os^II(L)(CN)₃(N = N-Me₂Ph)] [(PPh₄)1] as a minor product (10% yield). On the other hand, OsN* undergoes exclusive ring nitrogenation of diphenylamine, indole, and carbazole to give the corresponding osmium(II) benzoquinone diimines. All products have been characterized by various spectroscopic techniques and by X-ray crystallography. The reaction between OsN* and Ar₂N is proposed to proceed via an initial 1e^- transfer (ET) followed by proton transfer (PT) to generate Os^VNH and Ar₂N^• intermediates, which then further combine to give the product. The benzoquinone diimine ligands are susceptible to oxidation. Oxidation of 2 with H₂O₂ at ambient conditions affords [Os^IV(L)(CN)₃(N═PhMe₂(O)═O)]^-, which bears the previously unknown (epoxy)benzoquinone iminato ligand.

Characterization of cyanide-trapped methylated metabonates formed during reactive drug metabolite screening in vitro

Reactive metabolites are estimated to be one of the main reasons behind unexpected drug-induced toxicity, by binding covalently to cell proteins or DNA. Due to their high reactivity and short lifespan, reactive metabolites are analyzed after chemical trapping with nucleophilic agents such as glutathione or cyanide. Recently, unexplained and uncharacterized methylated reaction products were reported in a human liver microsome based reactive metabolite trapping assay utilizing potassium cyanide as a trapping agent. Here, a similar assay was utilized to produce mono- or dimethylated and further cyanide-trapped reaction products from propranolol, amlodipine and ciprofloxacin, followed by ultra-performance liquid chromatography/time-of-flight mass spectrometry (UPLC/TOF-MS) and ultra-performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) experiments for their more detailed structural elucidation. Formation of all observed cyanide-trapped products was clearly NADPH-dependent and thus metabolism-mediated. The suggested reaction pathways included N-methylation leading to iminium formation in primary and/or secondary amines preceded by cytochrome P450 (CYP)-mediated reactions. As the methylation reaction was suggested to be involved in formation of the actual reactive iminium ion, the observed cyanide-trapped products were experimental artifacts rather than trapped reactive metabolites. The results stress that to avoid overestimating the formation of reactive metabolites in vitro, this methylation phenomenon should be taken into account when interpreting the results of cyanide-utilizing reactive metabolite trapping assays. This in turn emphasizes the importance of identification of the observed cyano conjugates during such studies. Yet, metabolite identification has a high importance to avoid overestimation of in vitro metabolic clearance in the cases where this kind of metabonate formation has a high impact in the disappearance rate of the compound.

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

The pharmacokinetics and metabolism of linagliptin (BI1356, 8-(3R-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione) were investigated in healthy volunteers. The 10- and 5-mg (14)C-labeled drug was administered orally or intravenously, respectively. Fecal excretion was the dominant excretion pathway with 84.7% (p.o.) and 58.2% (i.v.) of the dose. Renal excretion accounted for 5.4% (p.o.) and 30.8% (i.v.) of the dose. Unchanged linagliptin was the most abundant radioactive species in all matrices investigated. The exposure (area under the curve 0-24 h) to the parent compound in plasma accounted for 191 nM . h (p.o.) and 356 nM . h (i.v.), respectively. The main metabolite 7-but-2-ynyl-8-(3S-hydroxy-piperidin-1-yl)-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (CD1790) was observed with >10% of parent compound systemic exposure after oral administration. The metabolite was identified as S-3-hydroxypiperidinly derivative of linagliptin. Experiments that included stable-labeled isotope techniques indicated that CD1790 was formed by a two-step mechanism via the ketone 7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-8-(3-oxopiperidin-1-yl)-3,7-dihydro-1H-purine-2,6-dione (CD10604). The initial ketone formation was CYP3A4-dependent and rate-limiting for the overall reaction to CD1790. Aldo-keto reductases with minor contribution of carbonyl reductases were involved in the subsequent stereoselective reduction of CD10604 to CD1790. The antipodes of linagliptin and CD1790 were not observed with adequate enantioselective liquid chromatography-tandem mass spectrometry methods. Other minor metabolites were identified by mass spectrometry and NMR investigations. However, it was concluded that the metabolites of linagliptin only play a minor role in the overall disposition and elimination of linagliptin.